Shares in Cogstate, a neuroscience technology company backed by the Myer family, rocketed 60 per cent higher because its brain health screening tests will benefit from the approval of the first Alzheimer’s treatment drug in the United States.
Biogen and Japan’s Eisai announced overnight Monday that the US Food and Drug Administration granted an accelerated approval for its treatment of Alzheimer’s disease.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
